Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors
Kavya Ramkumar, C. Allison Stewart, Kasey R. Cargill, et al.
Molecular Cancer Research (2020) Vol. 19, Iss. 3, pp. 485-497
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Targeting replication stress in cancer therapy
Alexandre André Balieiro Anastácio da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 38-58
Closed Access | Times Cited: 193
New Horizons in Lung Cancer Management Through ATR/CHK1 Pathway Modulation
Riya Thapa, Obaid Afzal, Asif Ahmad Bhat, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 19, pp. 1807-1818
Open Access | Times Cited: 50
AXL in cancer: a modulator of drug resistance and therapeutic target
Yaoxiang Tang, Hongjing Zang, Qiuyuan Wen, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 47
TAM family kinases as therapeutic targets at the interface of cancer and immunity
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 755-779
Closed Access | Times Cited: 46
Targeting ATR in patients with cancer
Natalie Ngoi, Patrick G. Pilié, Daniel J. McGrail, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 278-293
Closed Access | Times Cited: 24
AXL signaling in cancer: from molecular insights to targeted therapies
Monika Yadav, Anuj K. Sharma, Ketki Patne, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
Agnete S.T. Engelsen, Maria L. Lotsberg, Raefa Abou Khouzam, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 48
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
Shenduo Li, Guilherme Sacchi de Camargo Correia, Jing Wang, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2899-2899
Open Access | Times Cited: 40
Efferocytosis: An accomplice of cancer immune escape
Hui Qiu, Zhiying Shao, Xin Wen, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115540-115540
Open Access | Times Cited: 23
Structural, molecular, and functional insights into Schlafen proteins
Ukhyun Jo, Yves Pommier
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 6, pp. 730-738
Open Access | Times Cited: 38
AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer
Mauricio Marquez-Palencia, L Herrera, Pravat Kumar Parida, et al.
Cancer Research (2024) Vol. 84, Iss. 5, pp. 675-687
Open Access | Times Cited: 8
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer
Daniela Scattolin, Alessandro Dal Maso, Alessandra Ferro, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102768-102768
Closed Access | Times Cited: 6
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections
Rinky Raghuvanshi, Sandip B. Bharate
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 893-921
Closed Access | Times Cited: 36
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Kavya Ramkumar, Azusa Tanimoto, Carminia M. Della Corte, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 16, pp. 3237-3249
Open Access | Times Cited: 11
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Dan Yan, H. Shelton Earp, Deborah DeRyckere, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5639-5639
Open Access | Times Cited: 25
Targeting the DNA Damage Response Machinery for Lung Cancer Treatment
Katharigatta N. Venugopala
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1475-1475
Open Access | Times Cited: 17
The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer
Xun Hui Yeo, Vignesh Sundararajan, Zhengwei Wu, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 10
Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)
Liwei Wang, Songwei Jiang, Yinghui Yuan, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2491-2491
Open Access | Times Cited: 9
Targeting AXL in NSCLC
Aubhishek Zaman, Trever G. Bivona
Lung Cancer Targets and Therapy (2021) Vol. Volume 12, pp. 67-79
Open Access | Times Cited: 12
Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors
Viola Hedrich, Kristina Breitenecker, Leila Djerlek, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5448-5448
Open Access | Times Cited: 11
Breast cancer stem cells tolerate chromosomal instability during tumor progression via c-Jun/AXL stress signaling
Shahnawaz Ahmad Baba, Qi Sun, Samson Mugisha, et al.
Heliyon (2023) Vol. 9, Iss. 9, pp. e20182-e20182
Open Access | Times Cited: 4
Chromosomal instability as an architect of the cancer stemness landscape
Shahnawaz Ahmad Baba, Aran Zakeri, Jay S. Desgrosellier
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 1
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer
Luisa Amato, Daniela Omodei, Caterina De Rosa, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 3941-3941
Open Access | Times Cited: 1
Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy
Helmut Popper, Luka Brčić
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 8
Identification of an AXL kinase inhibitor in triple‐negative breast cancer by structure‐based virtual screening and bioactivity test
Pei Li, Yuzhen Niu, Shuyan Li, et al.
Chemical Biology & Drug Design (2021) Vol. 99, Iss. 2, pp. 222-232
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top